Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
**SYSTEMATIC REVIEWS AND META-ANALYSES**

**Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock**

Ferdinando D’Amico,*‡ Silvio Danese,*§ and Laurent Peyrin-Biroulet‡

*Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; ‡Department of Gastroenterology, Inserm Nutrition - Genetics and exposure to environmental risks U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France; §Inflammatory Bowel Disease Center, Department of Gastroenterology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano Milan, Italy

**BACKGROUND & AIMS:** Data on the clinical characteristics of patients with inflammatory bowel diseases (IBDs) with coronavirus disease 2019 (COVID-19) are scarce. The aim of our systematic review was to investigate symptoms and diagnostic-therapeutic management of IBD patients with COVID-19.

**METHODS:** We searched PubMed, Embase, Web of Science, and MedRxiv up to July 29, 2020, to identify all studies reporting clinical information on adult and pediatric IBD patients with confirmed COVID-19.

**RESULTS:** Twenty-three studies met our inclusion criteria, including 243,760 IBD patients. COVID-19 was diagnosed in 1028 patients (509 with Crohn’s disease [49.5%], 428 with ulcerative colitis [41.6%], 49 with indeterminate colitis [4.8%], and 42 with missing data [4.1%]), accounting for a cumulative prevalence of 0.4%. Viral infection occurred more frequently in males than in females (56.5% vs 39.7%), and the mean age ranged from 14 to 85 years. The most common symptoms were fever (48.3%), cough (46.5%), and diarrhea (20.5%), and a COVID-19 diagnosis was achieved mainly through polymerase chain reaction analysis of nasopharyngeal swabs (94.4%) and chest computed tomography scans (38.9%). Hydroxychloroquine (23.9%), lopinavir/ritonavir (8.2%), steroids (3.2%), and antibiotics (3.1%) were the most used drugs. Overall, approximately a third of patients were hospitalized (30.6%), and 11.4% of them required admission to the intensive care unit. In total, 29 COVID-19–related deaths were reported (3.8%), and increasing age and the presence of comorbidities were recognized as risk factors for COVID-19 and negative outcomes.

**CONCLUSIONS:** Diarrhea occurs more frequently in IBD patients with COVID-19 than in the non-IBD population. Further studies are needed to define the optimal diagnostic-therapeutic approach in IBD patients with COVID-19.

**Keywords:** COVID-19; SARS-CoV-2; Crohn’s Disease; Ulcerative Colitis; Inflammatory Bowel Disease.

---

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new β-coronavirus that was identified in China after the onset, in December 2019, of some pneumonia cases of unknown etiology.1 Viral infection can be asymptomatic or cause the coronavirus disease 2019 (COVID-19), which is characterized by a wide range of clinical manifestations including respiratory and gastrointestinal symptoms up to severe events such as pneumonia, acute respiratory distress syndrome, and death.2 The high transmission capacity and the rapid virus spread worldwide have led the World Health Organization to declare a pandemic state and national and international authorities to impose several precautions and prohibitions to limit the contagion up to the total lockdown.3,4 As of June 12, 2020, there were 7,410,510 cases of COVID-19 that have been ascertained globally, with a total of 418,294 deaths.5 Since the beginning of the health emergency, particular attention has been paid to the management of patients with chronic inflammatory bowel diseases (IBDs) because they frequently are treated with immunosuppressive drugs and therefore potentially are exposed to a greater infectious risk than the general population.6 In addition,
hospitals also profoundly have been reorganized to address the growing number of infected patients, to adapt to social distancing measures, and to prevent the infection risk, postponing or canceling nonessential activities and replacing outpatient visits with virtual clinics.7,8 The British Society of Gastroenterology, the European Crohn’s and Colitis Organization, and the International Organization for the Study of Inflammatory Bowel Disease promptly provided empiric recommendations for the management of patients with Crohn’s disease (CD) and ulcerative colitis (UC).9–11 However, knowledge of SARS-CoV-2 evolves daily and some doubts persist on the optimal approach in subjects treated with immunosuppressants, biologics, or small molecules. The aim of our study was to provide a systematic overview of the literature data on IBD patients with COVID-19 to report the clinical characteristics of disease, to identify any risk factors for severe/complicated disease, and to investigate the diagnostic-therapeutic management of IBD patients in this emergency setting.

Methods

We conducted a systematic review in accordance with the Cochrane Handbook12 and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension statement for reporting of systematic reviews incorporating network meta-analysis.13

Data Sources and Search Strategy

We searched PubMed, Embase, Web of Science, and MedRxiv up to July 29, 2020, to identify all studies reporting information on IBD patients with COVID-19. The following medical subject heading terms were combined with the Boolean operators “AND” or “OR”: “COVID-19,” “coronavirus disease 2019,” “SARS-CoV-2,” “severe acute respiratory syndrome coronavirus 2,” “new coronavirus,” “Crohn’s disease,” “CD,” “ulcerative colitis,” “UC,” “inflammatory bowel disease,” “IBD.” The search was restricted to human studies, although no language or time restrictions were applied. Titles and abstracts were scrutinized independently by all 3 authors (F.D., S.D., and L.P.B.) to identify eligible studies. Subsequently, full-text articles were examined for inclusion, and any disagreements were resolved through collegial discussion. Finally, the reference lists of the selected manuscripts were hand-searched to identify studies missed by the electronic search.

Selection Criteria

All studies meeting the following criteria were included: (1) adult and/or pediatric patients with a confirmed diagnosis of IBD; (2) studies reporting at least 1 confirmed case of COVID-19; and (3) studies addressing clinical management of IBD patients with COVID-19.

What You Need to Know

Background

Little data are available on the clinical characteristics of inflammatory bowel disease (IBD) patients with COVID-19 and their diagnostic-therapeutic management is not well established.

Findings

IBD patients with COVID-19 have symptoms similar to IBD patients except for a higher percentage of diarrhea. The diagnostic-therapeutic approach does not differ between IBD and non-IBD patients with COVID-19.

Implications for patient care

Fecal test for new coronavirus detection could allow to differentiate infected patients from those with IBD re-exacerbation. In addition, IBD medications could play a role in the treatment of COVID-19.

Reviews, systematic reviews, meta-analyzes, guidelines, letters, and editorials that did not show original data were excluded from our work. Furthermore, all studies involving non-IBD patients were excluded if the IBD population data could not be distinguished. If some results were reported at multiple time points, the study with the most comprehensive data was included.

Data Extraction and Analysis

Each article was assessed qualitatively. All 3 authors extracted the following data from the selected studies: first author, journal and year of publication, study design, number of participants, patient characteristics (age, sex, concomitant treatments, IBD type), number of IBD patients with confirmed COVID-19, symptoms of COVID-19, diagnostic approach, COVID-19 therapy, hospitalizations, admission to the intensive care unit (ICU), number of deaths, and risk factors associated with COVID-19.

Quality of Studies

The Newcastle–Ottawa Scale (NOS) score was used to measure the quality of nonrandomized clinical trials, and the Jadad score was adopted for randomized clinical trials.14,15 The NOS score ranges from 0 to 9. The NOS score is based on 8 items: representativeness of the exposed cohorts, selection of the nonexposed cohort, ascertainment of exposure, demonstration that the outcome of interest was not present at the start of the study, comparability of cohorts on the basis of the design or analysis, assessment of the outcome, follow-up period is long enough for outcomes to occur, and adequacy of the follow-up evaluation. One point can be assigned to each item, except for cohort comparability (which can be
assigned 2 points). A NOS score of 6 or higher was associated with high-quality studies, while scores of 3 or lower or between 4 and 5 indicated low- and moderate-quality studies, respectively. On the other hand, the Jadad score ranges from 0 to 5 and it assesses the following parameters: randomized study, appropriate randomization, double-blind study, appropriate double-blind study, and a description of withdrawals/dropouts. Each parameter is assigned 1 point and a study is defined as a high-quality study if the Jadad score is 3 or higher. All 3 authors graded the studies independently and any disagreements were discussed until their resolution.

Results

Study Characteristics

The flow chart of the search process is detailed in Figure 1. A total of 1380 articles were identified through our search (PubMed, 183; Embase, 84; Web of Science, 22, and MedRxiv, 1091). After removing duplicates and reviewing titles and abstracts, 63 studies were evaluated for full-text analysis. An additional 40 studies were excluded because they did not include COVID-19 patients (n = 25), did not evaluate clinical data (n = 9), results were included in another study (n = 3), data of IBD patients with a confirmed diagnosis of COVID-19 could not be extrapolated (n = 2), or data were not original (n = 1). Finally, 23 studies followed by observational cohort studies (3 prospective [13.0%] and 6 retrospective studies [26.1%] and case series [2 [8.7%]]) and most studies were of moderate quality according to the NOS score (15 [65.2%]), while the remaining studies were classified as high-quality studies (8 [34.8%]) (Tables 1 and 2).

Patient Characteristics

The overall study population consisted of 243,760 IBD patients. COVID-19 was diagnosed in 1028 patients (509 CD patients [49.5%], 428 UC patients [41.6%], 49 with indeterminate colitis [4.8%], and 42 with missing data [4.1%]), accounting for a cumulative prevalence of 0.4%. More than half of infected patients were male (581 [56.5%]), 408 were female (39.7%), and in 39 cases sex was not specified (3.8%). The mean age ranged from 14 to 85 years. Elderly patients (>65 y) with COVID-19 were found in 10 studies (43.5%), pediatric cases (<18 y) were reported in 4 studies (17.4%), and an infected pregnant patient was described in 1 case report (4.3%). The ongoing drugs at the time of COVID-19 diagnosis were reported in almost all studies (20 [87.0%]) and were as follows: anti-tumor necrosis factor (243 of 790 [30.8%]), mesalamine (203 [25.7%]), thiopurine (83 [10.5%]), vedolizumab (79 [10.0%]), ustekinumab (77 [9.7%]), steroids (68 [8.6%]), combination therapy...
| Study                | Study design                  | Study population | COVID-19 | Sex | Mean age, y | Ongoing therapy | Symptoms | Diagnosis | Treatment | Hospitalization | ICU | Mechanical ventilation | Death | Risk factors                                                                 |
|---------------------|-------------------------------|------------------|----------|-----|-------------|-----------------|-----------|-----------|-----------|-------------------|-----|------------------------|-------|-----------------------------------------------------------------------------|
| Lukin et al17       | Prospective cohort study      | 80 IBD, 160 controls | 26 CD, 38 UC | 135 males (56.3%) | 48.7 | Mesalamine, 20 (25%); anti-TNF, 16 (20%); steroids, 13 (16.2%); UST, 12 (15%); VDZ, 10 (8.0%); combination therapy, 4 (5.0%); thiopurines, 4 (5.0%); methotrexate, 3 (3.7%); TOFA, 1 (1.2%) | Cough, 54 (67.5%); fever, 53 (66.6%); diarrhea, 36 (45.0%); shortness of breath, 23 (28.8%); abdominal pain, 16 (20.0%); nausea, 12 (15%); vomiting, 10 (12.5%); myalgia/fatigue, 7 (8.8%); anorexia, 7 (8.8%); anosmia, 7 (8.8%); dysgeusia, 4 (5.0%) | NPS | / | 17 (21.3%) | 3 (17.6%) | 2 (11.8%) | 0 | Diagnosis of UC was associated with emergency visit or admission |
| Rodríguez-Lago et al19 | Retrospective cohort study    | 13 CD, 23 UC, 4 IC | 13 CD, 23 UC, 4 IC | 24 males (60%) | 59 | Mesalamine, 26 (65%); thiopurines, 8 (20%); steroids, 4 (10%); methotrexate, 3 (8%); UST, 3 (8%); combination therapy, 2 (5.0%); anti-TNF, 3 (8%); VDZ, 1 (3%) | Fever, 31 (77%); cough, 27 (67%); diarrhea, 8 (20%) | NPS | Hydroxychloroquine, 25 (63%); lopinavir/ritonavir, 15 (38%); antibiotic, 9 (23%); steroid, 5 (13%); oseltamivir, 1 (3%); tocilizumab, 1 (3%); anakinra, 1 (3%) | 21 (52.5%) | 0 | / | 2 (5%) | / |
| Brenner et al11      | Prospective cohort study      | 312 CD           | 312 CD | 276 males (52.6%) | 42.9 | Anti-TNF, 176 (33.5%); mesalamine, 117 (22.3%); UST, 55 (10.5%); thiopurines, 53 (10.1%); combination therapy, 52 (9.9%); VDZ, 50 (9.5%); systemic steroids, 37 (7.0%); other, 22 (4.2%); budesonide, 18 (3.4%); TOFA, 8 (1.5%); methotrexate, 5 (1.0%) | / | / | Hydroxychloroquine, 98 (18.7%); other, 67 (12.8%); lopinavir/ritonavir, 28 (5.3%); chloroquine, 14 (2.7%); steroid, 12 (2.3%); oseltamivir, 6 (1.1%); tocilizumab, 5 (1.0%); remdesivir, 2 (0.4%) | 161 (30.7%) | 24 (4.6%) | 21 (4.0%) | 16 (3%) | Increasing age, ≥2 comorbidities, systemic corticosteroids, and mesalamine/sulfasalazine use were risk factors for ICU admission/ventilation/death |
| Study | Design | Case Series | Number of Patients | Sex Distribution | Treatment | Fever | Cough | Fatigue | Dysosmia/Myalgia | Dyspnea | NPS | CT Scan | Age >65 y was associated independently with increased risk of COVID-19 |
|-------|-------|-------------|--------------------|------------------|-----------|-------|-------|--------|-----------------|--------|-----|--------|---------------------------------------------------------------|
| Taxonera et al | Case series | 920 CD (48.0%), 997 UC (52.0%) | 3 males (25.0%) | Mesalamine, 4 (33.3%); thiopurines, 3 (25.0%); anti-TNF, 3 (25.0%); methotrexate, 3 (25.0%); UST, 1 (8.3%); VDZ, 1 (8.3%) | 9 (75%); diarrhea, 9 (75%); cough, 6 (50%); myalgia, 6 (50%); dyspnea, 5 (41.7%); sore throat, 4 (33.3%); ageusia, 4 (33.3%); fatigue, 4 (33.3%); anosmia, 3 (25.0%); headache, 3 (25.0%); nausea/vomiting, 2 (16.7%) | Fever, 9 (75%); diarrhea, 9 (75%); cough, 6 (50%); myalgia, 6 (50%); dyspnea, 5 (41.7%); sore throat, 4 (33.3%); ageusia, 4 (33.3%); fatigue, 4 (33.3%); anosmia, 3 (25.0%); headache, 3 (25.0%); nausea/vomiting, 2 (16.7%) | | |
| Gubatan et al | Retrospective cohort study | 86 UC (51.2%), 66 CD (39.3%), 16 IC (9.5%) | 2 males (40.0%) | Mesalamine, 4 (80.0%); steroids, 1 (20.0%); thiopurines, 1 (20.0%); anti-TNF, 1 (20.0%) | Cough, 4 (80.0%); fever, 3 (60.0%); fatigue, 3 (60.0%); rhinopharyngitis, 3 (60.0%); myalgia, 3 (60.0%); sore throat, 2 (40.0%); dyspnea, 2 (40.0%); pneumonia, 2 (40.0%); diarrhea, 1 (20.0%); abdominal pain, 1 (20.0%); nausea/vomiting, 1 (20.0%) | Fever, 4 (80.0%); cough, 3 (60.0%); fatigue, 3 (60.0%); rhinopharyngitis, 3 (60.0%); myalgia, 3 (60.0%); sore throat, 2 (40.0%); dyspnea, 2 (40.0%); pneumonia, 2 (40.0%); diarrhea, 1 (20.0%); abdominal pain, 1 (20.0%); nausea/vomiting, 1 (20.0%) | | |
| Bezzio et al | Prospective cohort study | 32 CD, 47 UC | 44 males (55.7%) | Anti-TNF, 29 (36.7%); mesalamine, 24 (30.4%); VDZ, 15 (18.9%); steroids, 9 (11.4%); thiopurines, 6 (7.6%); UST, 3 (3.8%); investigational drugs, 2 (2.5%); calcineurin inhibitors, 1 (1.3%) | Fever, 71 (89.9%); cough, 52 (65.8%); dysosmia or dysgeusia, 19 (24.0%); arthralgia or myalgia, 18 (22.8%); dyspnea, 15 (19.0%); diarrhea, 12 (15.2%); rhinopharyngitis, 13 (16.4%); dysphonia 1 (1.2%); conjunctivitis, 1 (1.2%) | NPS, CT scan | 22 (27.8%) | |
| Khan et al | Retrospective cohort study | 37,857 IBD | 36 IBD (0.1%) | Anti-TNF, 2 (5.5%); thiopurines, 3 (8.5%) | Laboratory test | | | | | | | | | |

Notes: CD = Crohn's disease, UC = ulcerative colitis, IBD = inflammatory bowel disease, NPS = neurologic complications, CT = computed tomography.
| Study design | Study population | COVID-19 | Sex | Mean age, y | Ongoing therapy | Symptoms | Diagnosis | Treatment | Hospitalization | ICU | Mechanical ventilation | Death | Risk factors |
|-------------|------------------|---------|-----|-------------|-----------------|----------|-----------|-----------|-----------------|-----|------------------------|-------|-------------|
| Allocca et al28 | Retrospective cohort study | 6000 IBD | 9 CD, 6 UC | 4 males (26.7%) | Anti-TNF, 8 (53.3%); UST, 3 (20.0%); steroids, 2 (13.3%); thiopurines, 2 (13.3%); mesalamine, 1 (6.7%); VDZ, 1 (6.7%); investigational drugs, 1 (6.7%); calcineurin inhibitors, 1 (6.7%) | / | NPS | / | 5 (33.3%) | 0 | / | 0 | / |
| Turner et al30 | Case series | 4 pediatric CD, 2 pediatric UC, 1 pediatric IC | 3 CD, 2 UC | 2 males (40.0%) | Mesalamine, 3 (60.0%); thiopurines, 3 (60.0%); anti-TNF, 2 (40.0%); steroids, 1 (20.0%); VDZ, 1 (20.0%) | Cough, 3 (60.0%); fever, 2 (40.0%); fatigue, 1 (20.0%); rhinitis, 1 (20.0%); chest pain, 1 (20.0%); anosmia, 1 (20.0%); ageusia, 1 (20.0%) | / | / | 0 | 0 | 0 | 0 | / |
| Marafini et al31 | Retrospective cohort study | 397 CD, 269 UC, 6 IC | / | / | / | / | NPS | / | 2 (66.6%) | / | / | 1 | / |
| Singh et al37 | Retrospective cohort study | 196,403 IBD, 19,776 non-IBD | 101 CD, 93 UC, 38 IC | 85 males (36.7%) | Cough, 56 (24.1%); fever, 38 (16.4%); dyspnea, 30 (12.9%); nausea, 25 (10.8%); vomiting, 25 (10.8%); fatigue, 20 (8.6%); diarrhea, 19 (8.2%); abdominal pain, 18 (7.7%); sore throat, 14 (6.0%); hypoxemia, 12 (5.2%) | / | / | 56 (24.1%) | / | / | / | / |

CD, Crohn’s disease; CCI, Charlson Comorbidity Index; COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; IC, indeterminate colitis; ICU, intensive care unit; NPS, nasopharyngeal swab; TNF, tumor necrosis factor; TOFA, tofacitib; UC, ulcerative colitis; UST, ustekinumab; VDZ, vedolizumab; -, not applicable; /, not reported.

*One CD patient was excluded from the analysis because he was included in the Surveillance Epidemiology of Coronavirus Under Research Exclusion- Inflammatory Bowel Disease trial.

The risk of severe COVID-19 was higher in IBD patients who received corticosteroids up to 3 mo before the diagnosis of COVID-19.
| Study            | Study design | Study population | COVID-19 | Sex | Mean age, y | Ongoing therapy | Symptoms                                      | Diagnosis                                      | Treatment                                          | Hospitalization | ICU | Mechanical ventilation | Death | Risk factors |
|------------------|--------------|------------------|----------|-----|-------------|-----------------|-----------------------------------------------|-----------------------------------------------|---------------------------------------------------|----------------|-----|------------------------|--------|--------------|
| Mazza et al      | Case report  | 1 severe UC      | 1        | F   | 80          | Mesalamine      | Fever, diarrhea, anemia, dry cough, pneumonia | NPS, CT scan                                  | Noninvasive ventilation                           | 1              | 0            | 0                      | 0      | 1            |
| Jacobs et al     | Case report  | 1 UC             | 1        | F   | 33          | TOFA            | Fever, chills, cough, myalgias, sore throat, fatigue, night sweats | NPS                                           | TOFA                                             | 0              | 0            | 0                      | 0      | /            |
| Kunisaki et al   | Case report  | 1 UC             | 1        | M   | 60          | IFX + azathioprine Mesalamine | Cough and fever                               | NPS, CT scan                                  | -                                                 | 1              | 0            | 0                      | 0      | /            |
| Tursi et al      | Case report  | 1 CD             | 1        | M   | 30          | Mesalamine Adalimumab | Fever                                         | NPS, CT scan                                  | Noninvasive ventilation                           | 1              | 0            | 0                      | 0      | /            |
| Rosen et al      | Case report  | 1 severe UC during pregnancy CD | 1        | F   | 26          | None            | Abdominal pain, diarrhea, hematochezia, urgency | NPS                                           | Steroid, Antibiotic Hydroxychloroquine, Cyclosporine, Azithromycin, hydroxychloroquine | 1              | 0            | 0                      | 0      | /            |
| Dolinger et al   | Case report  | 1 pediatric CD   | 1        | M   | 14          | None            | Fever, abdominal pain, erythematous maculopapular facial rash | /                                             | Hydroxychloroquine, Infliximab                   | 1              | 0            | 0                      | 0      | /            |
| Wolf et al       | Case report  | 1 CD             | CD       | M   | 85          | None            | Diarrhea, anorexia, fatigue, cough, weight loss | NPS                                           | Bismuth subsalicylate                             | 0              | 0            | 0                      | 0      | /            |
| Di Ruscio et al  | Case report  | 1 severe UC      | UC       | F   | 60          | Infliximab      | Fever, cough, dyspnea, diarrhea, abdominal pain, fatigue | NPS, chest radiography, CT scan               | Hydroxychloroquine, darunavir/ritonavir, supplemental oxygen | 1              | 0            | 0                      | 0      | /            |
| Bezzio and Saibeni | Case report | 1 severe UC    | UC       | M   | 40          | Oral steroid    | Diarrhea, abdominal pain, fever, cough            | NPS, chest radiography                         | Azithromycin, Hydroxychloroquine                  | 1              | 0            | 0                      | 0      | /            |
| Bezzio et al     | Case report  | 1 severe UC      | UC       | M   | 36          | Mesalamine      | Diarrhea, fever, dyspnea, cough                   | NPS, CT scan                                  | Infliximab                                      | 1              | 0            | 0                      | 0      | /            |
| Calabrese et al  | Case report  | 1 UC             | UC       | F   | 19          | None            | Fever, nausea, vomiting, diarrhea, anorexia, ageusia | NPS, CT scan                                  | Hydroxychloroquine                               | 1              | 0            | 0                      | 0      | /            |
| Giulia and Patrizia | Case report | 1 severe pediatric CD | CD       | F   | 17          | Adalimumab      | Fever, fatigue, dyspnea                           | NPS                                           | None                                             | 1              | 0            | 0                      | 0      | /            |

CD, Crohn's disease; COVID-19, coronavirus disease 2019; F, female; IBD, inflammatory bowel disease; ICU, intensive care unit; IFX, infliximab; M, male; NPS, nasopharyngeal swab; TOFA, tofacitinib; UC, ulcerative colitis; -, not applicable; /, not reported.
(biological drug + thiopurine) [59 [7.5%]], other [27 [3.4%]], methotrexate [14 [1.8%]], and tofacitinib [10 [1.3%]]. As for COVID-19 symptoms, they were reported in 19 studies (82.6%). The most frequent symptoms were fever [217 of 449 [48.3%]], cough [209 [46.5%]], and diarrhea [92 [20.5%]], followed by dyspnea [55 [12.2%]], nausea [40 [8.9%]], and abdominal pain [39 [8.7%]] (Table 4).

### Diagnosis and Treatment

Eighteen studies (78.3%) evaluated the diagnostic approach in IBD patients with COVID-19. The polymerase chain reaction (PCR) analysis of the nasopharyngeal swabs was the most commonly adopted method (17 of 18 [94.4%]). A chest computed tomography was performed in 7 studies (38.9%). In 1 study (5.6%), the diagnosis was achieved by laboratory test. The treatment of infected subjects was described in 14 articles (60.1%). The most used drugs were hydroxychloroquine [140 of 586 [23.9%]], lopinavir/ritonavir [48 [8.2%]], steroids [19 [3.2%]], antibiotics [18 [3.1%]], and chloroquine [14 [2.4%]] (Table 5). Importantly, in 3 case reports the patients were treated with infliximab or tofacitinib.

### Prognosis and Risk Factors

The percentage of severe COVID-19 (need for hospitalization, admission to the ICU, or mechanical ventilation) was reported in 21 articles (91.3%). Overall, 302 of 987 patients (30.6%) were hospitalized and only a small part of them stayed in the ICU (28 of 246 [11.4%]). In 17 studies, the need for mechanical ventilation was described, with an average value of 3.7% patients (26 of 697). Moreover, the percentage of IBD patients who died from COVID-19 was investigated in all studies except 2, with a total of 29 deaths in 760 cases (3.8%). It is noteworthy that in only 2 studies was there a control group consisting of non-IBD patients with COVID-19. Interestingly, death and ICU admission were numerically lower in the IBD group than in the control group (24% vs 35%, respectively; $P = .352$). Finally, 6 studies explored the risk factors in infected IBD patients. The Charlson Comorbidity Index (odd ratio [OR], 1.240; 95% CI, 1.106–1.3912; $P = .0002$) and age older than 66 years (OR, 21.30; $P = .022$) were associated with an increased risk of COVID-19, while patients with a UC diagnosis had higher rates of emergency visits or admissions (adjusted OR [aOR], 12.7; $P = .009$). Age older than 65 years (OR, 19.6; 95% CI, 2.95–130.6; $P = .002$), active IBD (OR, 8.45; 95% CI, 1.26–56.56; $P = .02$), and Charlson Comorbidity Index greater than 1 (OR, 16.66;
Table 4. Symptoms of IBD Patients With a Confirmed Diagnosis of COVID-19 in the Overall Population

| Symptoms                | N (%)     |
|-------------------------|-----------|
| Fever                   | 217/449 (48.3) |
| Cough                   | 209/449 (46.5) |
| Diarrhea                | 92/449 (20.5) |
| Dyspnea                 | 55/449 (10.5) |
| Nausea                  | 40/449 (8.9) |
| Abdominal pain          | 39/449 (8.7) |
| Vomiting                | 39/449 (8.7) |
| Fatigue                 | 39/449 (8.7) |
| Myalgia                 | 35/449 (7.8) |
| Dysgeusia               | 23/449 (5.1) |
| Sore throat             | 21/449 (4.7) |
| Rhinopharyngitis        | 17/449 (3.8) |
| Anosmia                 | 12/449 (2.7) |
| Hypoxemia               | 12/449 (2.7) |
| Anorexia                | 8/449 (1.8) |
| Ageusis                 | 6/449 (1.3) |
| Headache                | 3/449 (0.7) |
| Chest pain              | 2/449 (0.4) |
| Night sweats            | 1/449 (0.2) |
| Dysepsis                | 1/449 (0.2) |
| Conjunctivitis          | 1/449 (0.2) |
| Hematochezia            | 1/449 (0.2) |
| Urgency                 | 1/449 (0.2) |
| Skin rash               | 1/449 (0.2) |
| Weight loss             | 1/449 (0.2) |

95% CI, 1.80–153.9; P = .01) were associated with COVID-19–related deaths.25 Similarly, increasing age (aOR, 1.04; 95% CI, 1.01–1.02), 2 or more comorbidities (aOR, 2.9; 95% CI, 1.1–7.8), systemic corticosteroids (aOR, 6.9; 95% CI, 2.3–20.5), and mesalamine/sulfasalazine use (aOR, 3.1; 95% CI, 1.3–7.7) were risk factors for severe COVID-19.21 Interestingly, Singh et al.27 confirmed that IBD patients treated with steroids in the previous 3 months had a higher risk of severe COVID-19 than untreated (30.98% vs 19.25%; relative risk, 1.60; 95% CI, 1.01–2.57; P = .04), while no difference was found with the use of other immune-mediated therapies (relative risk, 1.01; 95% CI, 0.62–1.65; P = .97).

Table 5. Treatment of IBD Patients With a Confirmed Diagnosis of COVID-19 in the Overall Population

| Treatment                  | N (%)     |
|----------------------------|-----------|
| Hydroxychloroquine         | 140/586 (23.9) |
| Lopinavir/ritonavir         | 48/586 (8.2) |
| Steroid                    | 19/586 (3.2) |
| Antibiotic                 | 18/586 (3.1) |
| Chloroquine                | 14/586 (2.4) |
| Oseltamivir                | 7/586 (1.2) |
| Tocilizumab                | 6/586 (1.0) |
| Remdesivir                 | 2/586 (0.3) |
| Noninvasive ventilation    | 2/586 (0.3) |
| Infliximab                 | 2/586 (0.3) |
| Tofacitinib                | 1/586 (0.2) |
| Anakinra                   | 1/586 (0.2) |
| Cyclosporine               | 1/586 (0.2) |
| Other                      | 70/586 (11.9) |

COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease.

Discussion

This was a systematic review reporting the prevalence, clinical characteristics, diagnostic/therapeutic management, and risk factors of IBD patients with a confirmed diagnosis of COVID-19. Twenty-three studies were included showing a COVID-19 prevalence of 0.4% in our IBD cohort. COVID-19 was found in more men than women (56.5% vs 39.7%), and patients of all ages, from children to the elderly, were involved also, as highlighted in the first reports from China on non-IBD individuals.2,29 In line with general population data,2 fever (48.3%) and cough (46.5%) were the most frequent symptoms in infected patients with IBD. Interestingly, approximately a fifth of the patients experienced diarrhea. Our previous pooled analysis40 and 2 recent systematic reviews and meta-analyses41,42 showed a cumulative prevalence of diarrhea of approximately 7% to 10% in patients with COVID-19. This high disparity could be related to the influence of the underlying disease on the number of evacuations, justifying the greater percentage of diarrhea in CD and UC patients than in the general population. On the other hand, SARS-CoV-2 has been isolated in the duodenum and rectum,43 and a higher concentration of fecal calprotectin, a known inflammatory marker, has been found in infected patients with diarrhea compared with those without diarrhea (123.2 vs 17.3 μg/g; P < .001),44 suggesting that viral gut tropism could worsen inflammatory status and symptoms of IBD patients. Unfortunately, it is extremely challenging to assign the symptom to the underlying disease or to the concomitant infection, making it difficult to interpret data. A COVID-19 diagnosis was achieved mainly through nasopharyngeal swabs (94.4%) and chest computed tomography scans (38.9%).

Surprisingly, although approximately 40% of stool samples have been reported as positive for fecal SARS-CoV-2,42 no test for the presence of viral RNA shedding in the stool was performed in the included studies. To date, no clear evidence is available on the sensitivity of fecal PCR for the diagnosis of COVID-19. However, we hypothesize that fecal PCR may be useful in IBD patients to distinguish disease re-exacerbation from viral super-infection, allowing better patient management and targeted therapy. Hydroxychloroquine (23.9%) and lopinavir/ritonavir (8.2%) were the most frequently administered drugs in our cohort. Hydroxychloroquine is an antimalarial drug that proved to be effective in inhibiting in vitro replication of the new coronavirus.45 However, data supporting its use in infected patients are still limited. A prospective observational study16 conducted on 1376 patients with COVID-19 showed no
significant difference in the risk of intubation and death between hydroxychloroquine users and nonusers (hazard ratio, 1.04; 95% CI, 0.82–1.32), raising several doubts on its efficacy.

Similarly, inconclusive data have been reported regarding lopinavir/ritonavir. A randomized controlled trial compared lopinavir/ritonavir with standard care (supplemental oxygen, noninvasive and invasive ventilation, antibiotics, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation) for the treatment of hospitalized COVID-19 patients. Lower 28-day mortality (19.2% vs 25.0%; 95% CI, −17.3 to 5.7) and shorter hospital stay (median, 12 vs 14 d; 95% CI, 0–3) and ICU stay (median, 6 vs 11 d; 95% CI, −9 to 0) were found in patients treated with the antiviral compared with the control group, but no significant difference between the 2 groups was detected regarding the primary end point of time to clinical improvement (median, 16 vs 16 d; hazard ratio, 1.31; 95% CI, 0.95–1.80; P = .09). Moreover, it is important to emphasize that in 3 case reports, clinical remission of IBD patients with COVID-19 was achieved after treatment with infliximab or tocافتinin. These findings certainly are not sufficient to support the use of these drugs, but they provide numerous insights. Accumulating evidence has shown that COVID-19 severity is associated with a cytokine storm syndrome, characterized by an increase in interleukin 2, interleukin 7, granulocyte-macrophage colony stimulating factor, interferon-γ-inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1-α, and tumor necrosis factor-α. Based on these findings, it is legitimate to hypothesize that the use of biological drugs that selectively inhibit specific cytokines or small molecules that simultaneously block multiple cellular pathways may play a role in the treatment of these patients. In addition, the mortality rate that we found in IBD patients with COVID-19 (3.8%) was lower compared with the general population (~10%). This could be explained by a lower rate of COVID-19 risk factors (increasing age and comorbidities) in IBD subjects. Importantly, more than half of the patients included in our study were treated with biologics or small molecules at the time of COVID-19 diagnosis, but it is not known if these drugs influenced the prognosis of infected IBD patients. Several ongoing studies are recruiting patients to assess the efficacy and safety of biologics (NCT04344249 and NCT04425538) and small molecules (NCT04373044, NCT04346147, and NCT04362943) for COVID-19 treatment and will allow us to understand if these drugs can be used in this setting.

Our systematic review addressed several practical aspects of managing IBD patients with COVID-19, including moderate- to high-quality studies and reporting data from a relevant number of patients. However, some limitations must be mentioned. First, no randomized clinical trial has been conducted to date in patients with IBD. Second, we excluded all studies reporting data collected in the Surveillance Epidemiology of Coronavirus Under Research Exclusion- Inflammatory Bowel Disease registry, but any overlaps resulting from non-explicit inclusion in the registry cannot be excluded. Nonetheless, the description of clinical symptoms was missing in the Surveillance Epidemiology of Coronavirus Under Research Exclusion- Inflammatory Bowel Disease database, although most of the evaluated articles provided this important information.

In conclusion, symptoms experienced by IBD patients with COVID-19 are similar to those occurring in the general population, except for a higher percentage of diarrhea. Currently, the diagnostic-therapeutic approach does not differ between IBD and non-IBD patients, but further studies are needed to evaluate whether fecal research of viral RNA and treatment with IBD drugs may play a role in the management of COVID-19 patients.

References

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–733.
2. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
3. Anon. WHO. Director-General’s opening remarks at the media briefing on COVID-19 – 11 May 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-may-2020, Accessed June 11, 2020.
4. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis 2020;20:e102–e107.
5. Anon, Coronavirus Disease (COVID-19) Situation Reports. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-may-2020, Accessed June 11, 2020.
6. D’Amico F, Peyrin-Biroulet L, Danese S. Inflammatory bowel diseases and COVID-19: the invisible enemy. Gastroenterology 2020;158:2302–2304.
7. Danese S, Ran ZH, Repici A, et al. Gastroenterology department operational reorganisation at the time of Covid-19 outbreak: an Italian and Chinese experience. Gut 2020;69:981–983.
8. Allocca M, Fiorino G, Furfaro F, et al. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic. Clin Gastroenterol Hepatol 2020;18:1882–1883.
9. Kennedy NA, Jones G-R, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2020;69:984–990.
10. D’Amico F, Danese S, Peyrin-Biroulet L, et al. Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn’s and Colitis Organization (ECCO). Gastroenterology 2020;159:14–19.e3.
11. Rubin DT, Abreu MT, Rai V, et al. Management of patients with Crohn’s disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting. Gastroenterology 2020;159:6–13.e6.
12. Higgins JPT, Cochrane Collaboration, eds. Cochrane handbook for systematic reviews of interventions. 2nd ed. Hoboken, NJ: Wiley-Blackwell, 2020.
13. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777.
14. Anon. Ottawa Hospital Research Institute. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed June 2, 2020.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
16. Mazza S, Sorce A, Peyvandi F, et al. A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut 2020;69:1148–1149.
17. Lukin DJ, Kumar A, Hajifathalian K, et al. Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease. Gastroenterology 2020 May 29;S0016-5085(20)34738-7. https://doi.org/10.1053/j.gastro.2020.05.066. Online ahead of print.
18. Jacobs J, Clark-Snustad K, Lee S. Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on tofacitinib. Inflamm Bowel Dis 2020;26:e64.
19. Kunisaki R, Tsukiji J, Kudo M. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFα antibodies: a case report. J Crohns Colitis 2020 May 30;jjaa105. https://doi.org/10.1093/ecco-jcc/jjaa105. Online ahead of print.
20. Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology 2020; 159:781–783.
21. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases; results from an international registry. Gastroenterology 2020; 159:491–491.e3.
22. Tursi A, Angarano G, Monno L, et al. COVID-19 infection in Crohn’s disease under treatment with adalimumab. Gut 2020; 69:1364–1365.
23. Taxonera C, Sagastagoitia I, Alba C, et al. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2020;52:276–283.
24. Gubatan J, Levitte S, Balabanis T, et al. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California. Gastroenterology 2020;159:1141–1144.
25. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut 2020; 69:1213–1217.
26. Khan N, Patel D, Xie D, et al. Impact of anti-TNF and thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide VA cohort study. Gastroenterology 2020 May 29;S0016-5085(20)34737-5. https://doi.org/10.1053/j.gastro.2020.05.065. Online ahead of print.
27. Rosen MH, Axelrad J, Hudesman D, et al. Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature. Inflamm Bowel Dis 2020;26:971–973.
28. Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol 2020; 18:2134–2135.
29. Dolinger MT, Person H, Smith R, et al. Pediatric Crohn’s disease and multisystem inflammatory syndrome in children (MIS-C) and COVID-19 treated with infliximab. J Pediatr Gastroenterol Nutr 2020;71:153–155.
30. Turner D, Huang Y, Martin-de-Carpi J, et al. Corona virus disease 2019 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2020;70:727–733.
31. Marafini I, Salvatori S, Sena G, et al. Low frequency of COVID-19 in inflammatory bowel diseases. Dig Liver Dis 2020 Jun 13;S1590-8658(20)30266-8. https://doi.org/10.1016/j.dld.2020.06.007. Online ahead of print.
32. Di Ruscio M, Variola A, Angeheben A, et al. A challenging colectomy for acute severe ulcerative colitis complicated by COVID-19. Inflamm Bowel Dis 2020;26:e120–e122.
33. Bezzio C, Manes G, Bini F, et al. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut 2020 Jun 17;gutjnl-2020-321760. https://doi.org/10.1136/gutjnl-2020-321760. Online ahead of print.
34. Bezzio C, Saibeni S. Severe IBD flares and COVID-19: expand the gastroenterology-surgery team to include an infectious disease specialist. Gastroenterology 2020 Jun 15;S0016-5085(20)34774-0. https://doi.org/10.1053/j.gastro.2020.05.082. Online ahead of print.
35. Calabrese E, Zorzì F, Monteleone G, et al. Ref. no. DLD-20-852: clinical characteristics and outcomes from an international registry. Gastroenterology 2020 Jun 15;S0016-5085(20)34738-9. https://doi.org/10.1053/j.gastro.2020.05.136. Online ahead of print.
36. Giulia B, Patrizia A. SARS-CoV-2 infection in severe pediatric inflammatory bowel disease in United States. A Multicenter Research Network Study. Gastroenterology 2020. Epub ahead of print.
37. Singh S, Khan A, Chowdhry M, et al. Risk of severe COVID-19 in patients with inflammatory bowel disease in United States. A Multicenter Research Network Study. Gastroenterology 2020. Epub ahead of print.
38. Wolf DC, Wolf CH, Rubin DT. Temporal improvement of a COVID-19-positive Crohn’s disease patient treated with bismuth subsalicylate. Am J Gastroenterol 2020;115:1298.
39. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Lond Engl 2020;395:507–513.
40. D’Amico F, Baumgart DC, Danese S, et al. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol 2020; 18:1663–1672.
41. Mao R, Qiu Y, He J-S, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:667–678.
with coronavirus disease 2019: a systematic review and meta-
analysis. JAMA Netw Open 2020;3:e2011335.
43. Lin L, Jiang X, Zhang Z, et al. Gastrointestinal symptoms of 95
cases with SARS-CoV-2 infection. Gut 2020;69:997–1001.
44. Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin
indicates intestinal inflammation in COVID-19. Gut 2020;
69:1543–1544.
45. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic de-
riative of chloroquine, is effective in inhibiting SARS-CoV-2
infection in vitro. Cell Discov 2020;6:16.
46. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider
cytokine storm syndromes and immunosuppression. Lancet
Lond Engl 2020;395:1033–1034.
47. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of
Covid-19 in New York City. N Engl J Med 2020;382:2372–2374.

Reprint requests
Address requests for reprints to: Laurent Peyrin-Biroulet, MD, PhD, Department
of Gastroenterology, Inserm Nutrition - Genetics and exposure to environ-
mental risks, Nancy University Hospital, University of Lorraine, 1 Allée du
Morvan, 54511 Vandoeuvre-lès-Nancy, France. e-mail: peyrinbiroulet@gmail.
com; fax: (33) 383153633.

Conflicts of interest
These authors disclose the following: Silvio Danese has served as a speaker,
consultant and advisory board member for Schering-Plough, AbbVie, MSD,
UCB Pharma, Ferring, Cellerix, Millenium Takeda, Nycomed, Pharmacosmos,
Actelion, Alphawasserman, Genentech, Grunenthal, Pfizer, Astra Zeneca, Novo
Nordisk, Cosmo Pharmaceuticals, Vifor, Johnson & Johnson, Nikkiso Europe
GmbH, and Theravance; and Laurent Peyrin-Biroulet has served as a speaker,
consultant, and advisory board member for Merck, AbbVie, Janssen, Gen-
entech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion,
Takeda, Biogaran, Boehringer-Ingelheim, Lilly, HAC-Pharma, Index Pharma-
ceuticals, Amgen, Sandoz, Forward Pharma GmbH, Celgene, Biogen, Lycera,
Samsung Bioepis, and Theravance. The remaining author discloses no
conflicts.